REG - Hikma Pharmaceutical - Director/PDMR Shareholding

Hikma PharmaceuticalsAnnouncement

07/11/2025 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251107:nRSG7212Ga&default-theme=true

RNS Number : 7212G  Hikma Pharmaceuticals Plc  07 November 2025

Hikma Pharmaceuticals PLC

(the "Company")

LONDON, 7 November 2025: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai:
HIK) (LEI: 549300BNS685UXH4JI75) announces it has been notified of the
following transactions by Persons Discharging Managerial Responsibilities
("PDMR") of the Company.

This notification is made under Article 19(1) of the EU Market Abuse
Regulation 596/2014 as it forms part of domestic law by virtue of the European
Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided
in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by Persons Discharging
Managerial Responsibilities

Mazen Darwazah

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                                            Mazen Darwazah
 2   Reason for the notification
 a)  Position/status                                                                 Executive Vice Chairman
 b)  Initial notification /Amendment                                                 Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                                            Hikma Pharmaceuticals PLC
 b)  LEI                                                                             549300BNS685UXH4JI75
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument and identification  Description: Ordinary shares of 10 pence each (Shares)
     code

                                                                                     ID Code: GB00B0LCW083
 b)  Nature of the transaction                                                       Purchase of Shares in Hikma Pharmaceuticals PLC

 c)  Price(s) and volume(s)                                                          Price(s)                      Volume(s)
     £15.90                                                                                                        115,000
     £16.07                                                                                                        200,000
 d)  Aggregated information                                                          Price(s): £16.009

                                                                                     Volume(s): 315,000

                                                                                     Total: £5,042,760
 e)  Date of the transaction                                                         6 November 2025
 f)  Place of the transaction                                                        London Stock Exchange (XLON)

 

 

Victoria Hull

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                                            Victoria Hull
 2   Reason for the notification
 a)  Position/status                                                                 Senior Independent Director
 b)  Initial notification /Amendment                                                 Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                                            Hikma Pharmaceuticals PLC
 b)  LEI                                                                             549300BNS685UXH4JI75
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument and identification  Description: Ordinary shares of 10 pence each (Shares)
     code

                                                                                     ID Code: GB00B0LCW083
 b)  Nature of the transaction                                                       Purchase of Shares in Hikma Pharmaceuticals PLC

 c)  Price(s) and volume(s)                                                          Price(s)                      Volume(s)
     £15.47                                                                                                        3,214
 d)  Aggregated information                                                          Price(s): £15.47

                                                                                     Volume(s): 3,214

                                                                                     Total: £49,720.58
 e)  Date of the transaction                                                         7 November 2025
 f)  Place of the transaction                                                        London Stock Exchange (XLON)

 

 

 

Helen Middlemist

Group Company Secretary

+44 (0) 20 7399 2760

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBDBDBUUGDGUR



            Copyright 2019 Regulatory News Service, all rights reserved